DROIA Oncology Ventures’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

DROIA Oncology Ventures is a private equity firm that focuses on investing in pharmaceutical and life science sectors. Read more

Bart Van Hooland's photo - Managing Partner of DROIA Oncology Ventures

Managing Partner

Bart Van Hooland

CEO Approval Rating

77/100

Founded:

2011

Est. Annual Revenue
Est. Employees
Headquarters
Update Address

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of DROIA Oncology Ventures?

Acquisitions

No recent acquisitions found related to DROIA Oncology Ventures

DROIA Oncology Ventures Funding History

$170.7M

Since DROIA Oncology Ventures was founded in 2011, it has participated in 1 round of funding. In total DROIA Oncology Ventures has raised $170.7M. DROIA Oncology Ventures' funding round was on Dec 2018 for a total of $170.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Investment Fund
Dec 2018
$170.7M
-

Total Funding: $170.7M

Since DROIA Oncology Ventures was founded in 2011, it has participated in 1 round of funding. In total DROIA Oncology Ventures has raised $170.7M. DROIA Oncology Ventures' funding round was on Dec 2018 for a total of $170.7M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Vico is a biotechnology company that develops and commercializes RNA therapeutics for the treatment of CNS disorders.
$31M
Jul 28, 2020
Series A
-
Accent Therapeutics is a biopharmaceutical company that develops and commercializes RNA-protein based therapies for the treatment of cancer.
$63M
Apr 22, 2020
Series B
-
Volastra is a biotechnology company that develops novel therapies for the treatment of metastatic cancers.
$12M
Feb 10, 2020
Seed
-
Cyteir Therapeutics is a biotechnology company that develops therapeutics for the treatment of cancer and autoimmune diseases.
$40.2M
Sep 26, 2019
Series B
-
Frontier Medicines is a pre-clinical stage biopharmaceutical company that develops medicines for debilitating diseases.
$67M
Jun 24, 2019
Series A
-

DROIA Oncology Ventures News

April 23, 2020FirstWord Pharma

Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins

Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patien... See more »
February 21, 2020BioSpace

Montis Biosciences launched with €8,4 million seed financing and a novel approach to immuno-oncology

Montis Biosciences announces its launch with €8,4 million in seed financing from an international inv... See more »
February 11, 2020firstwordpharma

Volastra Therapeutics Launches with $12 Million in Seed Financing to Develop Novel Metastatic Cancer Therapies

Volastra Therapeutics, a biotechnology company developing novel therapies for the treatment of metast... See more »
October 16, 2019FinSMEs

Cyteir Therapeutics Raises Additional $40.2M in Series B Financing

Cyteir Therapeutics, a Lexington, Mass.-based leader in the discovery and development of next-generat... See more »
June 26, 2019MedCity News

Frontier Medicines launches with $67M Series A, hopes to go after 'undruggable' targets

Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets f... See more »
June 26, 2019BioSpace

Latham & Watkins Advises Frontier Medicines in $67 Million Series A Financing for Development of Novel Medicines

Frontier Medicines has announced the closing of a Series A Preferred Stock financing round of $67 mil... See more »

DROIA Oncology Ventures Press Releases

Headquarters

35, Allée Scheffer

, Luxembourg2520

352-203-01-236

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

DROIA Oncology Ventures is a private equity firm that focuses on investing in pharmaceutical and life science sectors. DROIA Oncology Ventures was founded in 2011. DROIA Oncology Ventures' headquarters is located in Luxembourg, LU 2520. It has raised ...

CEO

DROIA Oncology Ventures's Managing Partner, Bart Van Hooland, currently has an approval rating of 77%. DROIA Oncology Ventures's primary competitors are

Website

droia.be

Frequently Asked Questions about DROIA Oncology Ventures

  1. When was DROIA Oncology Ventures founded?

    DROIA Oncology Ventures was founded in 2011
  2. Who is DROIA Oncology Ventures's CEO?

    DROIA Oncology Ventures's CEO is Bart Van Hooland
  3. How much revenue does DROIA Oncology Ventures generate?

    DROIA Oncology Ventures generates $23.1M in revenue
  4. How much funding does DROIA Oncology Ventures have?

    DROIA Oncology Ventures has historically raised $170.7M in funding
  1. Where is DROIA Oncology Ventures's headquarters?

    DROIA Oncology Ventures's headquarters is in Luxembourg, LU
  2. How many employees does DROIA Oncology Ventures have?

    DROIA Oncology Ventures has 248 employees
  3. What sector does DROIA Oncology Ventures operate in?

    DROIA Oncology Ventures is in Diversified Investment Services
  4. Who has DROIA Oncology Ventures invested in?

    DROIA Oncology Ventures's has invested in companies such as Vico, Accent Therapeutics, Volastra